The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Discovery of a new predisposition gene, ERG, for bone marrow failure and hematological malignancy
In this interview, Hamish Scott, PhD, and Chris Hahn, PhD, University of South Australia, Adelaide, Australia, discuss a case study of an Australian family that led to the discovery of a new predisposition gene for bone marrow failure and hematological malignancy. An investigation into the sons of a mother with thrombocytopenia and neutropenia, which progressed into acute myeloid leukemia (AML) and later therapy-related myelodysplastic syndrome (MDS), resulted in the identification of mutations in the ERG gene. A missense variation in the DNA-binding ETS domain causes a loss of function of the ETS protein and increases hematological disease predisposition. The discovery of this causal germline ERG mutation may improve diagnosis, surveillance, and treatment strategies of patients and holds the potential for developing targeted therapy strategies using gene and cell therapy. Germline testing for variants in ERG should be encouraged to identify individuals with ERG deficiency syndrome. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
